Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.96)
# 643
Out of 4,479 analysts
60
Total ratings
62.5%
Success rate
6.98%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $150 | $247.61 | -39.42% | 16 | Jul 1, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $5.03 | +29.22% | 4 | May 9, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $925 | $1,044.66 | -11.45% | 4 | May 3, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $110 | $82.22 | +33.79% | 8 | Apr 25, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | $12 → $10 | $5.43 | +84.16% | 3 | Feb 23, 2024 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $440 | $473.78 | -7.13% | 15 | Feb 20, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $78 | $68.40 | +14.04% | 4 | Feb 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $55 | $40.45 | +35.97% | 5 | Nov 15, 2023 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $72 | $53.12 | +35.55% | 1 | Apr 13, 2023 |
Alnylam Pharmaceuticals
Jul 1, 2024
Reiterates: Neutral
Price Target: $150
Current: $247.61
Upside: -39.42%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.03
Upside: +29.22%
Regeneron Pharmaceuticals
May 3, 2024
Reiterates: Neutral
Price Target: $925
Current: $1,044.66
Upside: -11.45%
BioMarin Pharmaceutical
Apr 25, 2024
Reiterates: Overweight
Price Target: $110
Current: $82.22
Upside: +33.79%
Aurinia Pharmaceuticals
Feb 23, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $5.43
Upside: +84.16%
Vertex Pharmaceuticals
Feb 20, 2024
Reiterates: Overweight
Price Target: $440
Current: $473.78
Upside: -7.13%
Gilead Sciences
Feb 7, 2024
Maintains: Neutral
Price Target: $80 → $78
Current: $68.40
Upside: +14.04%
Bristol-Myers Squibb Company
Nov 15, 2023
Downgrades: Neutral
Price Target: $68 → $55
Current: $40.45
Upside: +35.97%
CRISPR Therapeutics AG
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $53.12
Upside: +35.55%